Cargando…
Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study
BACKGROUND: Elevated platelet count is associated with risk of venous thromboembolism in cancer patients initiating chemotherapy. It is not known whether this risk by platelet count is causal or merely reflects the malignant disease. We investigated whether pre-cancer platelet count alone or togethe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958406/ https://www.ncbi.nlm.nih.gov/pubmed/24642868 http://dx.doi.org/10.1371/journal.pone.0092011 |
_version_ | 1782307867350532096 |
---|---|
author | Jensvoll, Hilde Blix, Kristine Brækkan, Sigrid K. Hansen, John-Bjarne |
author_facet | Jensvoll, Hilde Blix, Kristine Brækkan, Sigrid K. Hansen, John-Bjarne |
author_sort | Jensvoll, Hilde |
collection | PubMed |
description | BACKGROUND: Elevated platelet count is associated with risk of venous thromboembolism in cancer patients initiating chemotherapy. It is not known whether this risk by platelet count is causal or merely reflects the malignant disease. We investigated whether pre-cancer platelet count alone or together with high leukocyte count was associated with risk of venous thromboembolism in subjects who did and did not develop cancer during follow-up in a population-based cohort study. METHODS: Platelet count and other baseline characteristics were measured in 25160 initially cancer-free subjects who participated in the Tromsø Study in 1994–1995. Incident cancer and symptomatic venous thromboembolism events were registered up to December 31(st), 2009. Multivariable Cox regression models were used to calculate hazard ratio for venous thromboembolism across categories of platelet count (<40(th), 40–80(th), and >80(th) percentile) with 95% confidence interval. RESULTS: During follow-up, 2082 subjects were diagnosed with cancer. Platelet count was measured on average 8.3 years before the cancer diagnosis. There were 129 venous thromboembolism events in the cancer cohort (13.5 per 1000 person-years) and 377 in the non-cancer cohort (1.2 per 1000 person-years). In cancer patients, pre-cancer platelet count above the 80(th) percentile (≥295×10(9)/L) was associated with a 2-fold higher risk of venous thromboembolism (Hazard ratio: 1.98, 95% confidence interval 1.21–3.23) compared to platelet count below the 40(th) percentile (<235×10(9)/L). Concomitant high platelet and leukocyte counts showed a synergistic effect on the VTE risk. In cancer-free subjects, no association was found. COMMENT: In conclusion, pre-cancer platelet count was associated with risk of symptomatic venous thromboembolism in cancer patients, but not in cancer-free subjects. Our findings suggest that platelet count and platelet-leukocyte interactions may play a role in the pathogenesis of cancer-related venous thromboembolism. |
format | Online Article Text |
id | pubmed-3958406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39584062014-03-24 Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study Jensvoll, Hilde Blix, Kristine Brækkan, Sigrid K. Hansen, John-Bjarne PLoS One Research Article BACKGROUND: Elevated platelet count is associated with risk of venous thromboembolism in cancer patients initiating chemotherapy. It is not known whether this risk by platelet count is causal or merely reflects the malignant disease. We investigated whether pre-cancer platelet count alone or together with high leukocyte count was associated with risk of venous thromboembolism in subjects who did and did not develop cancer during follow-up in a population-based cohort study. METHODS: Platelet count and other baseline characteristics were measured in 25160 initially cancer-free subjects who participated in the Tromsø Study in 1994–1995. Incident cancer and symptomatic venous thromboembolism events were registered up to December 31(st), 2009. Multivariable Cox regression models were used to calculate hazard ratio for venous thromboembolism across categories of platelet count (<40(th), 40–80(th), and >80(th) percentile) with 95% confidence interval. RESULTS: During follow-up, 2082 subjects were diagnosed with cancer. Platelet count was measured on average 8.3 years before the cancer diagnosis. There were 129 venous thromboembolism events in the cancer cohort (13.5 per 1000 person-years) and 377 in the non-cancer cohort (1.2 per 1000 person-years). In cancer patients, pre-cancer platelet count above the 80(th) percentile (≥295×10(9)/L) was associated with a 2-fold higher risk of venous thromboembolism (Hazard ratio: 1.98, 95% confidence interval 1.21–3.23) compared to platelet count below the 40(th) percentile (<235×10(9)/L). Concomitant high platelet and leukocyte counts showed a synergistic effect on the VTE risk. In cancer-free subjects, no association was found. COMMENT: In conclusion, pre-cancer platelet count was associated with risk of symptomatic venous thromboembolism in cancer patients, but not in cancer-free subjects. Our findings suggest that platelet count and platelet-leukocyte interactions may play a role in the pathogenesis of cancer-related venous thromboembolism. Public Library of Science 2014-03-18 /pmc/articles/PMC3958406/ /pubmed/24642868 http://dx.doi.org/10.1371/journal.pone.0092011 Text en © 2014 Jensvoll et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Jensvoll, Hilde Blix, Kristine Brækkan, Sigrid K. Hansen, John-Bjarne Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study |
title | Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study |
title_full | Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study |
title_fullStr | Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study |
title_full_unstemmed | Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study |
title_short | Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study |
title_sort | platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the tromsø study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958406/ https://www.ncbi.nlm.nih.gov/pubmed/24642868 http://dx.doi.org/10.1371/journal.pone.0092011 |
work_keys_str_mv | AT jensvollhilde plateletcountmeasuredpriortocancerdevelopmentisariskfactorforfuturesymptomaticvenousthromboembolismthetromsøstudy AT blixkristine plateletcountmeasuredpriortocancerdevelopmentisariskfactorforfuturesymptomaticvenousthromboembolismthetromsøstudy AT brækkansigridk plateletcountmeasuredpriortocancerdevelopmentisariskfactorforfuturesymptomaticvenousthromboembolismthetromsøstudy AT hansenjohnbjarne plateletcountmeasuredpriortocancerdevelopmentisariskfactorforfuturesymptomaticvenousthromboembolismthetromsøstudy |